| Literature DB >> 29808442 |
Lieke Brouwer1, Sabine M G van der Sanden2, Job C J Calis3, Andrea H L Bruning2, Steven Wang2, Joanne G Wildenbeest2,4,5, Sjoerd P H Rebers2, Kamija S Phiri6, Brenda M Westerhuis2,7, Michaël Boele van Hensbroek3,4, Dasja Pajkrt4, Katja C Wolthers2.
Abstract
Enteroviruses (EVs) are among the most commonly detected viruses infecting humans worldwide. Although the prevalence of EVs is widely studied, the status of EV prevalence in sub-Saharan Africa remains largely unknown. The objective of our present study was therefore to increase our knowledge on EV circulation in sub-Saharan Africa. We obtained 749 fecal samples from a cross-sectional study conducted on Malawian children aged 6 to 60 months. We tested the samples for the presence of EVs using real time PCR, and typed the positive samples based on partial viral protein 1 (VP1) sequences. A large proportion of the samples was EV positive (89.9%). 12.9% of the typed samples belonged to EV species A (EV-A), 48.6% to species B (EV-B) and 38.5% to species C (EV-C). More than half of the EV-C strains (53%) belonged to subgroup C containing, among others, Poliovirus (PV) 1-3. The serotype most frequently isolated in our study was CVA-13, followed by EV-C99. The strains of CVA-13 showed a vast genetic diversity, possibly representing a new cluster, 'F'. The majority of the EV-C99 strains grouped together as cluster B. In conclusion, this study showed a vast circulation of EVs among Malawian children, with an EV prevalence of 89.9%. Identification of prevalences for species EV-C comparable to our study (38.5%) have only previously been reported in sub-Saharan Africa, and EV-C is rarely found outside of this region. The data found in this study are an important contribution to our current knowledge of EV epidemiology within sub-Saharan Africa.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29808442 PMCID: PMC6132918 DOI: 10.1007/s00705-018-3878-7
Source DB: PubMed Journal: Arch Virol ISSN: 0304-8608 Impact factor: 2.574
Primers and probes used for RT-PCR (primers EV-1, EV-2 and probe WT-MGB), semi-nested PCR (primers 224, 222, AN89 and AN88) and sequencing (primers AN89 and AN88)
| Primer/probe | Sequence 5’-3’ | Polarity | Gene | Genomic location |
|---|---|---|---|---|
| 224 | GCIATGYTIGGIACICAYRT | Forward | VP1 | 1977-1996 |
| 222 | CICCIGGIGGIAYRWACAT | Reverse | VP1 | 2969-2951 |
| AN89 | CCAGCACTGACAGCAGYNGARAYNGG | Forward | VP1 | 2602-2627 |
| AN88 | TACTGGACCACCTGGNGGNAYRWACAT | Reverse | VP1 | 2977-2951 |
| EV-1 | GGCCCTGAATGCGGCTAAT | Forward | 5’UTR | 450-468 |
| EV-2 | GGGATTGTCACCATAAGCAGCC | Reverse | 5’UTR | 600-579 |
| WT-MGB (probe) | CGGAACCGACTACTTTGGGT | 5’UTR | 532-551 |
Baseline characteristics
| Cases with severe anemia, n = 227 | Hospital controls, n = 261 | Community controls, n = 249 | Totala (n = 749) | |
|---|---|---|---|---|
| Patient characteristics | ||||
| Male sex, n (%) | 107 (47) | 133 (51) | 120 (48) | 371 (50) |
| Age in years, median (IQR) | 1.30 (0.85-2.16) | 1.76 (1.06-2.39) | 2.00 (1.20-3.01) | 1.64 (1.02-2.60) |
| EV-positive, n (%) | 198 (87) | 234 (90) | 229 (92) | 673 (90) |
| Sequenced, n (%)b | 77/198 (39%) | 104/234 (44%) | 99/229 (43%) | 283/673 (42%) |
| EV-A, n (%) | 15 (19) | 8 (8) | 15 (15) | 38 (13) |
| EV-B, n (%) | 37 (48) | 58 (56) | 40 (40) | 137(48) |
| EV-C, n (%) | 25 (32) | 38 (37) | 44 (44) | 108 (38) |
Fig. 1Flowchart for all the included samples
List of all typed strains
| No. of typed strains | % of all typed strains | |
|---|---|---|
|
| ||
|
| ||
| CVA-2 | 2 | 0.7% |
| CVA-4 | 2 | 0.7% |
| CVA-5 | 4 | 1.4% |
| CVA-6 | 5 | 1.7% |
| CVA-7 | 1 | 0.3% |
| CVA-8 | 2 | 0.7% |
| CVA-10 | 2 | 0.7% |
| CVA-14 | 1 | 0.3% |
| CVA-16 | 2 | 0.7% |
| EV-A76 | 3 | 1.0% |
| EV-A89 | 2 | 0.7% |
| EV-A119 | 8 | 2.8% |
| EV-A120 | 3 | 1.0% |
|
|
|
|
|
| ||
| CVA-9 | 9 | 3,1% |
| CVB-2 | 1 | 0.3% |
| CVB-4 | 1 | 0.3% |
| CVB-5 | 1 | 0.3% |
| E1 | 7 | 2.4% |
| E2 | 2 | 0.7% |
| E5 | 5 | 1.7% |
| E6 | 10 | 3.5% |
| E7 | 4 | 1.4% |
| E9 | 1 | 0.3% |
| E11 | 4 | 1.4% |
| E12 | 1 | 0.3% |
| E13 | 7 | 2.4% |
| E14 | 9 | 3.1% |
| E15 | 12 | 4.2% |
| E18 | 6 | 2.1% |
| E19 | 5 | 1.7% |
| E20 | 3 | 1.0% |
| E21 | 4 | 1.4% |
| E24 | 1 | 0.3% |
| E25 | 3 | 1.0% |
| 5 | 1.7% | |
| E29 | 4 | 1.4% |
| E33 | 4 | 1.4% |
| EV-B69 | 1 | 0.3% |
| EV-B73 | 1 | 0.3% |
| EV-B75 | 5 | 1.7% |
| EV-B78 | 4 | 1.4% |
| EV-B79 | 2 | 0.7% |
| EV-B82 | 4 | 1.4% |
| EV-B80 | 8 | 2.8% |
| EV-B88 | 2 | 0.7% |
| EV-B97 | 1 | 0.3% |
| EV-B100 | 2 | 0.7% |
| |
|
|
|
| ||
| CVA-1 | 9 | 3,1% |
| CVA-11 | 7 | 2.4% |
| CVA-13 | 34 | 11.9% |
| CVA-17 | 3 | 1.0% |
| CVA-19 | 1 | 0.3% |
| CVA-20 | 12 | 4.2% |
| CVA-24 | 8 | 2.8% |
| EV-C99 | 31 | 10.8% |
| EV-C116 | 3 | 1.0% |
| PV2 (Sabin-like) | 1 | 0.3% |
| PV3 (Sabin-like) | 1 | 0.3% |
| |
|
|
|
|
|
|
Fig. 2Phylogenetic relationships, based on the VP1 3’ terminal nucleotide sequences, for Malawian field strains and reference strains available in GenBank. Supportive percentage bootstrap replicates ≥ 85% are shown. Studied strains are indicated by circles. For reference strains, the location and year of isolation are indicated (DR Congo, Democratic Republic of the Congo; CAR, Central African Republic). The prototype strains are indicated by triangles. Cluster F is marked in light grey to indicate that this is a potential new cluster, based on the nt and aa percentage similarity to the other clusters
Nucleotide (Nt) and amino acid (Aa) identity scores; identity scores are given within each CVA-13 cluster (minimum identity scores), and in comparison between CVA-13 clusters
| Nt identity | Aa identity | |
|---|---|---|
| Within CVA-13 clusters | ||
| | ≥ 80.6% | ≥ 93.1% |
| | ≥ 79.4% | ≥ 96.9% |
| | ≥ 78.5% | ≥ 93.7% |
| | ≥ 81.5% | ≥ 91.5% |
| | ≥ 78.8% | ≥ 91.8% |
| | ≥ 89.1% | ≥ 95.3% |
| Between CVA-13 clusters | ||
| | 72.3%-77.3% | 86.4%-94.0% |
| | 69.0%-73.3% | 79.7%-89.2% |
| | 69.0%-77.0% | 82.4%-94.6% |
(range of minimum through maximum identity scores)